Paracetamol: Past, present, and future

American Journal of Therapeutics

Volumn 7, Issue 2, 2000, Pages 143-147

  Prescott, Laurie F ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b 24 Colinton Road ^*  (United Kingdom)

Author keywords

Acetaminophen; Future; History; Paracetamol

Indexed keywords

ANALGESIC AGENT; PARACETAMOL;

FEVER; HUMAN; PAIN; REVIEW;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; FEVER; HUMANS; PAIN;

EID: 0034157450     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007020-00011     Document Type: Article

References (46)

1. Morse HN: Ueber eine neue Darstellungsmethode der Acetylamidophenole. Berichte Dtsch Chem Gesell 1878; 11:232-233.
2. von Mering J: Beiträge zur Kenntniss der Antipyretica. Ther Monatshefte 1893;7:577-578.
3. Hinsberg O, Treupel G: Ueber die physiologische Wirkung des p-Amidophenols und einiger Derivate desselben. Naunyn Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 1894;33:216-250.
4. Smith JN, Williams RT: Studies in detoxication. 16. The metabolism of acetanilide in the rabbit. Biochem J 1948; 42:538-544.
5. Smith JN, Williams RT: Studies in detoxication. 22. The metabolism of phenacetin (p-ethoxyacetanilide) in the rabbit and a further observation on acetanilide metabolism. Biochem J 1949;44:239-242.
6. Brodie BB, Axelrod J: The fate of acetanilide in man. J Pharmacol Exp Ther 1948;94:29-38.
7. Brodie BB, Axelrod J: The fate of acetophenetidin (phenacetin) in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther 1949;97:58-67.
8. Flinn FB, Brodie BB: The effect on the pain threshold of N-acetyl p-aminophenol, a product derived in the body from acetanilide. J Pharmacol Exp Ther 1948;94:76-77.
9. Beaver WT: Mild analgesics. A review of their clinical pharmacology. Am J Med Sci 1965;250:577-604.
10. Colgan MT, Mintz AA: The comparative antipyretic effect N-acetyl-p-aminophenol and acetylsalicylic acid. J Pediatr 1957;50:552-555.
11. Goulston K, Skyring A: Effect of paracetamol (N-acetyl-p-aminophenol) on gastrointestinal bleeding. Gut 1964; 5:463-466.
12. Jacobs LA, Morris JG: Renal papillary necrosis and the abuse of phenacetin. Med J Aust 1962;2:531-538.
13. Davidson DGD, Eastham WN: Acute liver necrosis following overdose of paracetamol. BMJ 1966;2:497-499.
14. Thomson JS, Prescott LF: Liver damage and impaired glucose tolerance after paracetamol overdosage. BMJ 1966;2:506-507.
15. Boyd EM, Bereczky GM: Liver necrosis from paracetamol. Br J Pharmacol 1966;26:606-614.
16. Jollow DJ, Mitchell JR, Potter WZ, et al: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973;187:195-202.
17. Potter WZ, Davis DC, Mitchell JR, et al: Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 1973;187:203-210.
18. Mitchell JR, Jollow DJ, Potter WZ, et al: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973a;187:185-194.
19. Mitchell JR, Jollow DJ, Potter WZ, et al: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973;187:211-217.
20. Prescott LF, Newton RW, Swainson CP, et al: Successful treatment of severe paracetamol overdosage with cysteamine. Lancet 1974;i:588-592.
21. Prescott LF, Illingworth RN, Critchley JAJH, et al: Intravenous N-acetylcysteine: The treatment of choice for paracetamol poisoning. BMJ 1979;2:1097-1100.
22. Rumack BH, Peterson RG, Koch GC, Amara IA: Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981;141:380-385.
23. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231:232-235.
24. Flower RJ, Vane JR: Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-411.
25. Pélissier T, Alloui A, Caussade F, et al: Evidence for a spinal tropisetron-inhibited antinociceptive effect of paracetamol. Fundam Clin Pharmacol 1994;8:263.
26. 2 release after peripheral noxious stimulation. Anesthesiology 1999;91:231-239.
27. Halpin TJ, Holtzhauer FJ, Campbell RJ, et al: Reye's syndrome and medication use. JAMA 1982;248:687-691.
28. Belay ED, Bresee JS, Holman RC, et al: Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999;340:1377-1382.
29. Hochberg MC, Altman RD, Brandt KD, et al: Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38: 1541-1546.
30. Hochberg MC, Altman RD, Brandt KD, et al: Guidelines for the medical management of osteoarthritis: Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-1540.
31. Kellstein DE, Waksman JA, Furey SA, et al: The safety profile of non-prescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999;39:520-532.
32. Moore N, Van Ganse E, Le Parc J-M, et al: The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. Clin Drug Invest 1999;18:89-98.
33. Schneitman-McIntyre O, Farnen TA, Gordon N, et al: Medication misadventures resulting in emergency department visits at an HMO Medical Center. Am J Health Syst Pharm 1996;53:1416-1422.
34. Gow PJ, Smallwood RA, Angus PW: Paracetamol overdose in a liver transplantation centre: an 8-year experience. J Gastroenterol Hepatol 1999;14:817-821.
35. Kessel N: Self poisoning I. BMJ 1965;2:1265-1270.
36. Craig JO, Ferguson IC, Syme J: Infants, toddlers and aspirin. BMJ 1966;1:757-761.
37. Greer HD, Ward HP, Corbin KB: Chronic salicylate intoxication in adults. JAMA 1965;193:555-560.
38. Vane JR, Botting RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44: 1-10.
39. Vane JR, Botting RM: Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47(suppl 2):S78-S87.
40. Simmons DL, Botting RM, Robertson PM, et al: Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Nat Acad Sci U S A 1999;96:3275-3280.
41. Nenseter MS, Halvorsen B, Rosvold O, et al: Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modificafion of LDL. Arterioscler Thromb Vasc Biol 1995;15:1338-1344.
42. Al Rayyes O, Ahrén B, Florén C-H: Enhancement of low density lipoprotein catabolism by non-steroidal antiinflammatory drugs in cultured HepG2 cells. Eur J Pharmacol 1999;372:311-318.
43. Taylor AA, Raya JL, Blatzheim LP, et al: Acetaminophen inhibits both chemical- and cell-mediated human LDL oxidation in vivo and in vitro. Arch Pharmacol 1999;358 (suppl 2):R468.
44. Kapiotis S, Sengoelge G, Hermann M, et al: Paracetamol catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Arterioscler Thromb Vasc Biol 1997;17:2855-2860.
45. Harding JJ, Egerton M, Harding R: Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol 1989;67:518-524.
46. Shyadehi AZ, Harding JJ: Investigations of ibuprofen and paracetamol binding to lens proteins to explore their protective role against cataract. Biochem Pharmacol 1991;42:2077-2084.